Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 3NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 1Ovarian Cancer Prevention 1

Interventions

Paclitaxel 27Carboplatin 23Cisplatin 16Topotecan 8Taxes 8Docetaxel 7Gemcitabine 6Filgrastim 5Etoposide 4Doxorubicin 4Cyclophosphamide 4Psychiatric Rehabilitation 3Ifosfamide 3Chemotherapy, Adjuvant 3rubitecan 2pegfilgrastim 2paclitaxel poliglumex 2liposomal doxorubicin 2Trabectedin 2Surgical Procedures, Operative 2Polymerase Chain Reaction 2Peripheral Blood Stem Cell Transplantation 2Irinotecan 2GEN-1 2Fenretinide 2Erlotinib Hydrochloride 2Drug Therapy 2Celecoxib 2Bevacizumab 2Amifostine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Ovarian Neoplasms × Aspirin × Clear all
NCT02659384 2023-03-14

Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed
122 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡